CT Atlantic AG, a biotechnology company focused on cancer treatment by human-derived antibodies, announced the appointment of Dr. Thomas Lander to its board of directors.

Thomas Lander provides CT Atlantic with long-standing, global pharmaceutical experience in early through late stage drug development and in regulatory affairs.

Dr. Lander was previously Managing Director of CureVac GmbH (Tübingen, Germany) where he led the development of two mRNA-derived tumor vaccines for the treatment of prostate and non-small cell lung cancer. He is currently an advisor to biotechnology companies and related investment funds. Between 2003 and 2006, Dr. Lander was Executive Vice President, Global Clinical Research and Development and Chief Medical Officer with Merck KGaA (Darmstadt, Germany) where he led the global clinical development of Merck's oncology pipeline including the successful approval and launch of the EGF receptor inhibiting antibody Erbitux® against colorectal, head and neck cancer.

Dr. Lander holds an MD degree from the Ludwig-Maximilians-Universität, Medical School, Munich, and is a Certified Diabetologist. Prior to his appointment at Merck, Dr. Lander held several senior management positions in clinical development with international pharmaceutical companies including GlaxoSmithKline, Bristol-Myers Squibb, NovoNordisk and Boehringer Ingelheim. He serves on the board of Lipid Therapeutics GmbH, Heidelberg, and Vasopharm GmbH, Würzburg, as a director.

"We are delighted to welcome Dr. Lander to the board of directors" commented Prof. Alexander Knuth, Chairman of the Board of CT Atlantic. "His immense experience in the research and development of novel cancer therapeutics with a focus on cancer immunology will be of great help as we move forward in CT Atlantic. Throughout the years, Dr. Lander has demonstrated how clinical expertise and understanding can be translated into successful product development both in the pharmaceutical industry as well as in biotechnology." 

About CT Atlantic AG - http://www.ct-atlantic.com/
CT Atlantic AG is a Swiss biotechnology company focused on the identification and development of human-derived antibodies for the treatment of cancer. Founded by Prof. Dr Alexander Knuth in 2008, CT Atlantic AG is a spin-off from the University of Zurich, Switzerland, and the Ludwig Institute for Cancer Research, (New York, USA). The company's corporate headquarters and research facility are located in Schlieren.